Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Payables (2016 - 2025)

Palisade Bio (PALI) has disclosed Payables for 16 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 289.62% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 289.62% increase, with the full-year FY2024 number at $1.1 million, up 58.31% from a year prior.
  • Payables was $1.4 million for Q3 2025 at Palisade Bio, up from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.8 million in Q4 2022 to a low of $366000.0 in Q3 2024.
  • A 5-year average of $1.0 million and a median of $995500.0 in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 61.47% in 2024, then soared 289.62% in 2025.
  • Palisade Bio's Payables stood at $1.4 million in 2021, then increased by 27.19% to $1.8 million in 2022, then crashed by 60.32% to $698000.0 in 2023, then skyrocketed by 58.31% to $1.1 million in 2024, then grew by 29.05% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Payables are $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $745000.0 (Q1 2025).